SHR-1701 + Rivoceranib (± SHR-2554) in Advanced GC After First-Line Immunotherapy Failure

Clinical trial NCT07311408 · RECRUITING

Trial details

NCT number: NCT07311408
Sponsor: Jingdong Zhang
Status: RECRUITING
Phase: Phase 2
Study type: INTERVENTIONAL

Gastric Cancer (GC)Gastroesophageal Junction Adenocarcinoma

Start date: 2026-01-01
Primary completion: 2028-01-01
Enrollment: 40

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.